Key facts
- It has raised $2.0M; the latest was Early Stage VC ($2.0M) in Oct 2025.
- Notable investors include SOSV, IndieBio, New York Ventures, 2ndF, Alix Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for iOrganBio
- ·The full record, as it builds
Funding rounds
No funding rounds for iOrganBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iOrganBio
Developer of organ preservation and transplantation biotechnology systems designed for improving transplant outcomes and supporting regenerative medicine research. The company's platform incorporates advanced preservation techniques, compatibility with transplantation workflows, integration with tissue engineering and bioprinting technologies, and data management features, enabling healthcare providers and researchers to enhance organ viability, streamline transplantation logistics, and advance the field of regenerative medicine.
- Sector
- Healthcare
- HQ
- Chapel Hill, NC, United States
- Employees
- 5
- Website
- iorgan.bio/
- Ownership
- Privately Held (backing)
iOrganBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iOrganBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iOrganBio in its N-PORT filings yet. We sweep new filings monthly.